A team at LMU University Hospital has reported a groundbreaking therapeutic success in a patient suffering from the rare and potentially life-threatening combination of immune thrombocytopenia (ITP) and antiphospholipid syndrome (APS). In a study published on 5 March 2026 in the New England Journal of Medicine, Adrian Gottschlich (Inst. for Clinical Pharmacology - AG Kobold) and colleagues describe the targeted use of the bispecific CD3×CD19 antibody blinatumomab to silence the underlying autoimmune response in a therapy-resistant case.

Congratulations to Adrian Gottschlich and the LMU team on opening new perspectives for the treatment of severe autoimmune diseases.